Skip to content

Aspect Biosystems vs cellvie

Aspect Biosystems logo

Aspect Biosystems

Developing Bioprinted Tissue Therapeutics to transform how we treat some of the most elusive diseases

150 employees · est. 2013 · Canada

VS
cellvie logo

cellvie

Levearging the therapeutic potential of mitochondria

11 employees · est. 2018 · Switzerland

Aspect Biosystems is the older company (2013 vs 2018); Aspect Biosystems is the larger of the two.

Side-by-Side Comparison

Aspect Biosystems cellvie
Founded
2013 older 2018
Headquarters
Canada Switzerland
Employees
150 larger 11
Industry
Biotechnology, Life Sciences Biotechnology, Health and Wellness, Life Sciences
Funding Stage
Not tracked yet Seed
Total Funding
$323.73M $10.50M
Funding Rounds
15 2
Services
Development of Bioprinted Tissue Therapeutics, Regenerative Medicine Solutions, Cutting-edge Biotech Collaborations Mitochondrial Augmentation, Cellular Energy Recovery, Medical Research and Development, Ischemia-Reperfusion Treatment
Target Customers
Pharmaceutical Companies, Biotechnology Firms, Healthcare Providers focused on Metabolic and Endocrine Conditions, Research Institutions seeking advanced tissue therapies Healthcare Providers, Organ Transplant Centers, Patients with Ischemia-Reperfusion Conditions, Aging Population with Degenerative Conditions
Taxonomy
Bioprinted Tissue TherapeuticsCellular MedicinesRegenerative MedicineAI-Powered BioprintingHypoimmune Cell EngineeringAdvanced Biomaterials +9 Therapeutic Mitochondria TransplantationMitochondria AugmentationMitochondria ReplacementCell-Derived MedicinesIschemia-Reperfusion InjurySolid Organ Transplantation +8
Website
aspectbiosystems.com cellvie.bio
Aspect Biosystems logo

About Aspect Biosystems

Aspect Biosystems is a pioneering force in the biotechnology landscape, focusing on bioprinted tissue therapeutics that promise to transform treatments for particularly elusive diseases. Their full-stack tissue therapeutic platform leverages proprietary AI-powered bioprinting technology, therapeutic...

cellvie logo

About cellvie

cellvie, founded in 2018, is at the forefront of an innovative healthcare approach known as Therapeutic Mitochondria Transplantation (TMT), aiming to harness the potential of mitochondria for medical treatments. Originating from research developed by Dr. James McCully at Harvard Medical School, this...

Also comparing in this category

Comparing more than these two?

Get Aspect Biosystems, cellvie and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Aspect Biosystems compare?

A PDF of Aspect Biosystems and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Aspect Biosystems was founded in 2013, based in Canada, with 150 employees. Aspect Biosystems is a pioneering force in the biotechnology landscape, focusing on bioprinted tissue therapeutics that promise to transform treatments for particularly elusive diseases. Their full-st. cellvie was founded in 2018, based in Switzerland, with 11 employees. cellvie, founded in 2018, is at the forefront of an innovative healthcare approach known as Therapeutic Mitochondria Transplantation (TMT), aiming to harness the potential of mitochondria for medical.
Aspect Biosystems has raised $323.73M and cellvie $10.50M. Latest stage: cellvie Seed.
Both work in Biotechnology and Life Sciences and list regenerative medicine among their focus areas.

Compare Aspect Biosystems with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Aspect Biosystems on 15 Jun 2026, and cellvie on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout